HUTCHMED to Announce 2023 Final Results

Rhea-AI Summary

HUTCHMED (China) Limited will be announcing its final results for the year ended December 31, 2023 on February 28, 2024. Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management. The English conference call and audio webcast will take place at 7:30 am EST on February 28, 2024, and there will also be a Chinese webcast on February 29, 2024. Both webcasts will be available live via the company website at www.hutch-med.com/event/

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2023 on Wednesday, February 28, 2024 at 6:30 am Eastern Standard Time (EST) / 11:30 am Greenwich Mean Time (GMT) / 7:30 pm Hong Kong Time (HKT).

Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management.

The English conference call and audio webcast will take place at 7:30 am EST / 12:30 pm GMT / 8:30 pm HKT on Wednesday, February 28, 2024. In addition to the usual English webcast, there will also be a Chinese (Putonghua) webcast at 7:30 pm EST / 12:30 am GMT / 8:30 am HKT on Thursday, February 29, 2024. Both webcasts will be available live via the company website at www.hutch-med.com/event/. The presentation will be available for downloading before the conference call begins. Details of the conference call dial-in will be provided in the financial results announcement and on the company website. A replay will also be available on the website shortly after the event.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has approximately 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception it has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also marketed in the U.S. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

CONTACTS

Investor Enquiries	+852 2121 8200 / ir@hutch-med.com
Media Enquiries
Ben Atwell / Alex Shaw, FTI Consulting	+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) / HUTCHMED@fticonsulting.com
Zhou Yi, Brunswick	+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
Nominated Advisor
Atholl Tweedie / Freddy Crossley / Daphne Zhang, Panmure Gordon	+44 20 7886 2500

FAQ

When will HUTCHMED announce its final results for the year ended December 31, 2023?

HUTCHMED will announce its final results on February 28, 2024.

What time will the English conference call and audio webcast take place on February 28, 2024?

The English conference call and audio webcast will take place at 7:30 am EST on February 28, 2024.

Will there be a Chinese webcast for HUTCHMED's final results announcement?

Yes, there will be a Chinese webcast on February 29, 2024.

Where can analysts and investors access the live webcasts?

The webcasts will be available live via the company website at www.hutch-med.com/event/.

Will the presentation be available for downloading before the conference call begins?

Yes, the presentation will be available for downloading before the conference call begins.

Where can the details of the conference call dial-in be found?

Details of the conference call dial-in will be provided in the financial results announcement and on the company website.

Will a replay of the webcasts be available?

Yes, a replay will be available on the website shortly after the event.